Years of treatment with recombinant human growth hormone does not increase the cumulative lifetime exposure to insulin-like growth factor-1 above the population average in children born small for gestational age, a study shows.
Small-for-gestational age children should undergo regular measurements for the first 2 years after birth to help identify individuals who will benefit from recombinant human growth hormone therapy, German researchers advise.
More than half of girls with central precocious puberty have abnormal findings on magnetic resonance imaging of the brain, report researchers.
Most children and adolescents who identify as transgender or gender variant continue with hormone interventions after discharge from youth endocrine services, a study shows.
Researchers report a “biphasic and prolonged” minipuberty in girls, and provide reference ranges for reproductive hormones during the first year of life.
Dutch researchers have identified key logistic failures that may lead to adolescents with endocrine disorders failing to transition successfully from paediatric to adult tertiary care.
Weekly injections of somatrogon result in similar height gains to daily somatropin treatment in children with growth hormone deficiency, show results of a 12-month phase 3 trial.
Children with growth hormone deficiency maintain their growth trajectories if they switch from a daily recombinant human growth hormone to weekly lonapegsomatropin, and the vast majority prefer the less frequent injections, show the results of the fliGHt trial.
Children’s weight trajectories between birth and 4 years of age are associated with their dehydroepiandrosterone sulphate levels at age 7 years, study findings show.
Steroid hormone profiles can identify the majority of children with non-congenital adrenal hyperplasia primary adrenal insufficiency, say researchers.
